BioSpace News Archive

Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) noted that investigators at the National Cancer Institute (NCI) and National Institute of Neurological Disorders and Stroke (NINDS) reported that Lixte’s lead clinical compound, LB-100, enhanced pharmacological immunotherapy of intracranial brain tumors in immune-competent mice including 25% complete regression and immunity to tumor rechallenge (Journal of Neuro-oncology, on-line April 27

Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID® Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori.

As Florida’s economy slowly prepares to re-open, Tampa General Hospital will continue using strict safety guidelines to begin performing elective surgeries and procedures next week

Junshi Biosciences (HKEX: 1877), today announced that the China National Medical Products Administration (NMPA) has accepted a supplemental New Drug Application (sNDA) for toripalimab as a treatment for patients with recurrent/metastatic nasopharyngeal carcinoma (NPC) who failed at least two lines of systemic therapy.

Eyelit Inc. is a manufacturing software provider for visibility, control, and coordination of manufacturing operations. Today Eyelit announced that a global leader in semiconductor manufacturing is deploying Eyelit’s FactoryConnect™ at multiple high-volume wafer fabs.

Study shows how virtual urgent care appointments increased by more than 600 percent, signaling a possible long-term shift in healthcare delivery

Integral Molecular announces the launch of SARS-CoV-2 Reporter Virus Particles (RVPs) to test patients for the presence of neutralizing antibodies, determine the effectiveness of vaccines, and measure the efficacy of drugs to enable expedited testing of new vaccines and therapeutics.

NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced its unaudited revenues for the first quarter of 2020.

AIkido Pharma Inc. announced a reminder to the Company’s stockholders that, April 30, 2020, is the record date for the previously announced distribution to our stockholders of shares of common stock of Hoth Therapeutics, Inc.. Each stockholder of the Company, as of 4:00 p.m.

Accretive Acquisition Adds Profitable Award-Winning Dr. Denese Skin Care & Anti-Aging Lines, Which Generated Approximately $18 Million in Total Sales in 2019 and Over $500M in Sales on QVC Over the Last 17 Years [30-April-2020] SOUTH EASTON, Massachusetts , April 30, 2020 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader i